419 related articles for article (PubMed ID: 25794638)
1. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and temozolomide brain distribution: a focus on ABCB1.
Goldwirt L; Beccaria K; Carpentier A; Farinotti R; Fernandez C
Cancer Chemother Pharmacol; 2014 Jul; 74(1):185-93. PubMed ID: 24867782
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
[TBL] [Abstract][Full Text] [Related]
6. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Vredenburgh JJ; Desjardins A; Reardon DA; Peters KB; Herndon JE; Marcello J; Kirkpatrick JP; Sampson JH; Bailey L; Threatt S; Friedman AH; Bigner DD; Friedman HS
Clin Cancer Res; 2011 Jun; 17(12):4119-24. PubMed ID: 21531816
[TBL] [Abstract][Full Text] [Related]
7. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
8. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Kirstein MN; Poquette CA; Tan M; Friedman HS; Brent TP
Clin Cancer Res; 2000 Oct; 6(10):4110-8. PubMed ID: 11051264
[TBL] [Abstract][Full Text] [Related]
10. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
11. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
12. [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Pikó B; Bassam A; Nagy KA; Török E; Vághy R; Vargáné Tamás R; Puskásné Szatmári K
Magy Onkol; 2012 Sep; 56(3):166-70. PubMed ID: 23008824
[TBL] [Abstract][Full Text] [Related]
13. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
[TBL] [Abstract][Full Text] [Related]
14. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
Chinot OL; de La Motte Rouge T; Moore N; Zeaiter A; Das A; Phillips H; Modrusan Z; Cloughesy T
Adv Ther; 2011 Apr; 28(4):334-40. PubMed ID: 21432029
[TBL] [Abstract][Full Text] [Related]
15. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
Verreault M; Strutt D; Masin D; Anantha M; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2012 Feb; 158(1):34-43. PubMed ID: 22001870
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma.
Umeda K; Shibata H; Saida S; Hiramatsu H; Arakawa Y; Mizowaki T; Nishiuchi R; Adachi S; Heike T; Watanabe K
Pediatr Int; 2015; 57(1):169-71. PubMed ID: 25711258
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
[TBL] [Abstract][Full Text] [Related]
18. Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Melchardt T; Magnes T; Weiss L; Grundbichler M; Strasser M; Hufnagl C; Moik M; Greil R; Egle A
BMC Complement Altern Med; 2014 Mar; 14():115. PubMed ID: 24679099
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Peters KB; Lou E; Desjardins A; Reardon DA; Lipp ES; Miller E; Herndon JE; McSherry F; Friedman HS; Vredenburgh JJ
Oncologist; 2015 Jul; 20(7):727-8. PubMed ID: 26025933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]